Lovering, Frank et al. published their research in European Journal of Medicinal Chemistry in 2018 |CAS: 39503-58-7

The Article related to benzamide synthesis apoptosis ask1, Pharmacology: Structure-Activity and other aspects.Computed Properties of 39503-58-7

On February 10, 2018, Lovering, Frank; Morgan, Paul; Allais, Christophe; Aulabaugh, Ann; Brodfuehrer, Joanne; Chang, Jeanne; Coe, Jotham; Ding, Wei Dong; Dowty, Heather; Fleming, Margaret; Frisbie, Richard; Guzova, Julia; Hepworth, David; Jasti, Jayasankar; Kortum, Steve; Kurumbail, Ravi; Mohan, Shashi; Papaioannou, Nikolaos; Strohbach, Joseph W.; Vincent, Fabien; Lee, Katherine; Zapf, Christoph W. published an article.Computed Properties of 39503-58-7 The title of the article was Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors. And the article contained the following:

Many diseases are believed to be driven by pathol. levels of reactive oxygen species (ROS) and oxidative stress has long been recognized as a driver for inflammatory disorders. Apoptosis signal-regulating kinase 1 (ASK1) has been reported to be activated by intracellular ROS and its inhibition leads to a down regulation of p38-and JNK-dependent signaling. Consequently, ASK1 inhibitors may have the potential to treat clin. important inflammatory pathologies including renal, pulmonary and liver diseases. Anal. of the ASK1 ATP-binding site suggested that Gln756, an amino acid that rarely occurs at the GK+2 position, offered opportunities for achieving kinase selectivity for ASK1 which was applied to the design of a parallel medicinal chem. library that afforded inhibitors of ASK1 with nanomolar potency and excellent kinome selectivity. A focused optimization strategy utilizing structure-based design resulted in the identification of ASK1 inhibitors with low nanomolar potency in a cellular assay, high selectivity when tested against kinase and broad pharmacol. screening panels, and attractive physicochem. properties. The compounds we describe are attractive tool compounds to inform the therapeutic potential of ASK1 inhibition. The experimental process involved the reaction of Methyl 5-bromo-2-methoxy-4-methylbenzoate(cas: 39503-58-7).Computed Properties of 39503-58-7

The Article related to benzamide synthesis apoptosis ask1, Pharmacology: Structure-Activity and other aspects.Computed Properties of 39503-58-7

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary